Why would the CEO Brian Thom even mention "Separat
Post# of 477
(Total Views: 227)
Posted On: 11/01/2022 9:11:25 AM
Why would the CEO Brian Thom even mention "Separately, UHP expects to file its financial report for the third quarter of 2022 on Form 10-Q no later than November 14th. The report will show that the company generated modest commercial revenue for the first times since 2019, reflecting its reengagement with customers in the U.S. 510k market as well in certain international markets,"
The efficay of Hemostyp gauze is proven and supported with clinical tests, third party reviews and now commercial sales. Enough for me to determine the potential is high for FDA approval, merger or partner production agreement in the near term. Optimism?
$5-$10++
The efficay of Hemostyp gauze is proven and supported with clinical tests, third party reviews and now commercial sales. Enough for me to determine the potential is high for FDA approval, merger or partner production agreement in the near term. Optimism?
$5-$10++
(0)
(0)United Ecoenergy Corp. (UEEC) Stock Research Links
Scroll down for more posts ▼